| Literature DB >> 29896137 |
Hamidah Alias1, Sie Chong D Lau1, Ilse Schuitema2, Leo M J de Sonneville2.
Abstract
Objective: This study aimed to evaluate neuropsychological consequences in survivors of childhood brain tumor. Method: A case-control study was conducted over a period of 4 months in a tertiary referral center in Kuala Lumpur, Malaysia. Fourteen survivors of childhood brain tumor aged 7-18 years, who were off-treatment for at least 1 year and were in remission, and 31 unrelated healthy controls were recruited. The median age at diagnosis was 8.20 years (range: 0.92-12.96 years). The diagnoses of brain tumors were medulloblastoma, germ cell tumor, pineocytoma, pilocystic astrocytoma, suprasellar germinoma, and ependymoma. Eleven survivors received central nervous system irradiation. Seven tasks were selected from the Amsterdam Neuropsychological Tasks program to evaluate alertness (processing speed), and major aspects of executive functioning, such as working memory capacity, inhibition, cognitive flexibility, and sustained attention. Speed, stability and accuracy of responses were the main outcome measures.Entities:
Keywords: Amsterdam Neuropsychological Task (ANT); brain tumor; children; neuropsychological sequelae; survivors
Year: 2018 PMID: 29896137 PMCID: PMC5986920 DOI: 10.3389/fpsyg.2018.00703
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Demographic characteristics of study population.
| Characteristics | Childhood brain tumor survivors ( | Healthy controls ( | |
|---|---|---|---|
| Median age at study entry, | 16.00 | 15.14 | 0.177 |
| year (IQR) | (25th 14.03; 75th 17.89) | (25th 12.49; 75th 17.30) | |
| Gender, | 0.820 | ||
| Male | 9 (64.3) | 21 (67.7) | |
| Female | 5 (35.7) | 10 (32.3) | |
| Education, | |||
| Primary | 3 (21.4) | 5 (16.1) | 0.279 |
| Secondary | 10 (71.4) | 26 (83.9) | |
| Special | 1 (7.1) | 0 (0) | |
| Father’s median age, | 46.5 | 49.0 | 0.463 |
| year (IQR) | (25th 44.5; 75th 54.5) | (25th 41.0; 75th 50.0) | |
| Mother’s median age, | 45.50 | 47.0 | 0.344 |
| year (IQR) | (25th 42.7; 75th 52.7) | (25th 40.0; 75th 48.0) | |
| Father’s education level, | |||
| Primary | 0 (0) | 2 (6.5) | 0.014 |
| Secondary | 10 (71.4) | 8 (25.8) | |
| Tertiary | 4 (28.6) | 21 (67.7) | |
| Mother’s education level, | |||
| Primary | 1 (7.1) | 1 (3.2) | 0.662 |
| Secondary | 8 (57.1) | 15 (48.4)) | |
| Tertiary | 5 (35.7) | 15 (48.4) | |
| Family monthly income, | |||
| <MYR3000 | 2 (14.3) | 5 (16.1) | 0.955 |
| MYR3000–MYR7000 | 7 (50.0) | 14 (45.2) | |
| >MYR7000 | 5 (35.7) | 12 (38.7) | |
| Number of siblings, | |||
| <2 | 1 (7.1) | 7 (22.6) | 0.309 |
| 2–5 | 8 (57.1) | 18 (58.1) | |
| >5 | 5 (35.7) | 6 (19.4) | |
| Siblings with chronic illness or disability, | |||
| No | 13 (92.9) | 30 (96.8) | 0.262 |
| Yes | 1 (7.1) | 1 (3.2) |
Disease and treatment characteristics of survivors of childhood brain tumor.
| No. | Gender | Age at diagnosis, years | Age at study entry, years | Diagnosis | Surgery (no.) | VP shunt | Radiation, Gy | Chemotherapy protocol (cumulative dose of chemotherapy) | Disability |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 5.83 | 19.04 | Medulloblastoma (std risk) | Total resection | Yes | CSI 35Gy/PFB 18Gy | None | V |
| 2 | Male | 4.89 | 17.51 | Medulloblastoma (high risk) | Subtotal resection | Yes | CSI 35Gy/PFB 18Gy Whole spine boost 7.2Gy | Australia + New Zealand Protocol Methotrexate 48,000 mg/m2 | – |
| 3 | Male | 5.52 | 16.99 | Pineal gland GCT (malignant teratoma + embryonal carcinoma + choriocarcinoma) | Near-total resection | Yes | CSI 27Gy/WB boost 27Gy | BEP protocol Cisplatin 400 mg/m2 | V/H/M |
| 4 | Male | 10.36 | 20.97 | Medulloblastoma (high risk) | Subtotal resection | No | CSI 36Gy/PFB 18Gy | HIT-SIOP PNET 4 protocol Cisplatin 450 mg/m2 | V/H |
| 5 | Female | 0.92 | 11.45 | Pineocytoma | Subtotal resection | No | None | None | – |
| 6 | Male | 10.83 | 19.60 | Left parietal lobe germinoma | Partial resection | Yes | CSI 30Gy/WB boost 16Gy | SIOP GCT 96 protocol Cisplatin 600 mg/m2 Ifosfamide 45,000 mg/m2 | M |
| 7 | Female | 7.51 | 16.14 | Pilocytic astrocytoma (relapse) | Total resection | No | None | None | – |
| 8 | Female | 8.57 | 16.75 | Medulloblastoma (high risk) | Subtotal resection | Yes | CSI 36Gy/PFB 18Gy Spine (C5-T4) boost 14.4Gy | HIT-SIOP PNET 4 protocol Cisplatin 600 mg/m2 | V/H/M |
| 9 | Female | 7.78 | 14.33 | Suprasellar germinoma | Subtotal resection | No | CSI 24 Gy/WB boost 18Gy | None | V |
| 10 | Male | 7.84 | 13.14 | Ependymoma | Subtotal resection | Yes | None | None | V/M |
| 11 | Female | 11.17 | 15.79 | Medulloblastoma (std risk) | Subtotal resection | No | CSI 23.4Gy/PFB 30.6Gy | HIT-SIOP PNET 4 protocol Cisplatin 560 mg/m2 | V/H/M |
| 12 | Male | 10.41 | 15.46 | Medulloblastoma (High Risk) | Subtotal resection | Yes | CSI 35Gy/PFB 19.8Gy | None | – |
| 13 | Male | 8.75 | 11.95 | Third ventricle immature teratoma | Subtotal resection | No | CSI 34.2Gy/WB boost 16.2Gy | SIOP GCT 96 protocol Cisplatin 400 mg/m2 Ifosfamide 30,000 mg/m2 | – |
| 14 | Male | 12.96 | 15.81 | Medulloblastoma (std risk) | Total resection | No | CSI 35Gy/PFB 18Gy | HIT-SIOP PNET 4 protocol Cisplatin 490 mg/m2 | V/H |
Percentage of survivors deviating from the norm per task.
| Task∗ | 1 ≤ | ||
|---|---|---|---|
| BS (speed) | 21.4 | 28.6 | 50.0 |
| (SD of speed) | 0.0 | 50.0 | 50.0 |
| MSL (speed) | 42.9 | 14.2 | 42.9 |
| (errors) | 55.2 | 22.4 | 22.4 |
| SSV (speed) | 63.6 | 18.2 | 18.2 |
| (errors) | 45.5 | 9.0 | 45.5 |
| SAD (tempo) | 0.0 | 46.2 | 43.8 |
| (fluctuation in tempo) | 23.1 | 30.7 | 46.2 |
| (errors) | 66.7 | 8.4 | 24.9 |
| PU (accuracy) | 64.3 | 28.6 | 7.1 |
| (fluctuation in accuracy) | 78.6 | 0.0 | 21.4 |
| TR (accuracy) | 42.9 | 49.9 | 7.1 |
| (fluctuation in accuracy) | 92.9 | 0.0 | 7.1 |